Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players
Pune, India, Dec. 02, 2021 (GLOBE NEWSWIRE) -- The US Biosimilars market size is expected to gain momentum by reaching USD 30.83 billion by 2028 from USD 5.78 billion in 2021 while exhibiting a CAGR of 27.0% between 2021 to 2028. In its report titled “US Biosimilars Market, 2021-2028,” Fortune Business Insights™ mentions that it stood at USD 3.36 billion in 2020.
December 2020 –RIABNI, a biosimilar drug by Amgen for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), was approved by the US FDA.
Request a Sample Copy of the Research Report:
The demand for affordable and accessible healthcare facilities is expected to drive market growth. Moreover, the US government spends a considerable amount of its budget on healthcare facilities. Furthermore, the rising prevalence of diseases such as cancer and other diseases in the region demands effective biosimilar drugs. Therefore, the government agencies and companies are working together to launch several drugs. For instance, in the year 2019, Amgen and Allergan launched two biosimilar drugs for cancer treatment. It was a breakthrough in the US market, and such initiatives are expected to drive the market during the forecast period.
The negative effect of the global pandemic, COVID-19, has been felt across several economies facing unprecedented loss. However, the healthcare segment was least affected due to the improved logistics of pharmaceutical drugs and increased R&D capabilities in these tough times.
For instance, Coherus BioSciences’s Udencya emerged as one of the leading pegfilgrastim biosimilars during peak times of the pandemic. The company managed to generate a revenue of USD 465.0 million in 2020.
Therefore, the market for US biosimilars is expected to thrive during the forecast period
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990
By drug class, the market is segmented into filgrastim & pegfilgrastim, monoclonal antibodies, and others.
Based on drug class, the monoclonal antibody segment held the highest 59.5% of the US biosimilars market share. This is attributable to several US Food Drug Association approvals.
By disease indication, the market is divided into cancer, autoimmune diseases, ophthalmic diseases, and others. Based on the distribution channel, it is trifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. Lastly, in terms of region, the report talks about only the United States.
Get your Customized Research Report @ https://www.fortunebusinessinsights.com/enquiry/customization/u-s-biosimilars-market-100990
Patent Expiry of Biologics to Spur the Market Growth
A rising number of healthcare companies are losing patient protection in the region. The report suggests that around the top 25 biologics drive approximately 83% of sales. Therefore, the patent expiry of their products has opened new possibilities for the market players, thereby promoting the US biosimilars market growth. The companies are taking advantage of the loss of patents of biologics to mark their presence in the market with highly effective and potent drugs. For instance, in April 2020, Samsung Bioepis and Merck collaborated and launched the trastuzumab biosimilar Ontruzant in the US market for the treatment of early cancer after surgery, chemotherapy, and radiotherapy.
Strategic Partnerships Aid Growth in the Region’s Market
The market stood at USD 1.52 billion in 2019 and USD 3.36 billion in 2020. This is ascribable due to strategic partnership between companies in the region to provide high-quality, affordable therapies accessible to the patients.
For instance, in September 2020, Mylan and Biocon Biologics announced the launch of biosimilar Semglee to help control high blood pressure in pediatric patients with type 1 diabetes and adults with type 2 diabetes.
Such joint ventures are expected to favor the market growth.
Have Any Query? Ask Our Experts @ https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-biosimilars-market-100990
Key Players to Focus on Establishing Partnerships to Intensify Competition
The market is consolidated by the presence of major companies that are striving to maintain their position by establishing partnerships. For instance, In September 2020, Henlius entered into an exclusive license agreement for the commercialization of HLX02 (biosimilar, trastuzumab) in the US and Canada. With this partnership, HLX02 has the ability and capacity to cover most of the mainstream markets of biologics to come up with high-quality and affordable treatment options for patients worldwide, and this is expected to favor the growth of the market in the forthcoming years.
List of Key Players Profiled in this Market Report:
Pfizer Inc. (New York, US)
Samsung Bioepis (Incheon, South Korea)
Celltrion Inc. (Incheon, South Korea)
Novartis AG (Basel, Switzerland)
Inogen (Goleta, US)
Amgen Inc. (California, US)
Mylan N.V. (Pennsylvania, US)
Coherus BioSciences (California, US)
Other Prominent Players
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245